1.
Med J Aust
; 199(10): 700-1, 2013 Nov 18.
Article
in English
| MEDLINE
| ID: mdl-24237103
Subject(s)
Ankle Joint/microbiology , Antirheumatic Agents/adverse effects , Arthritis, Infectious/diagnosis , Arthritis, Rheumatoid/drug therapy , Histoplasmosis/diagnosis , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Aged , Antirheumatic Agents/therapeutic use , Arthritis, Infectious/etiology , Arthritis, Infectious/immunology , Arthritis, Rheumatoid/complications , Australia , Histoplasmosis/etiology , Histoplasmosis/immunology , Humans , Immunosuppressive Agents/therapeutic use , Laos , Male , Travel
2.
J Clin Rheumatol
; 19(3): 163, 2013 Apr.
Article
in English
| MEDLINE
| ID: mdl-23519172
3.
Med J Aust
; 187(9): 524-6, 2007 Nov 05.
Article
in English
| MEDLINE
| ID: mdl-17979620
ABSTRACT
Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-alpha (TNF-alpha) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-alpha agents, and periodic monitoring for the development of hepatitis is important.
